With a surge in preclinical investment, fresh news of clinical pipeline progressions, and a new era of therapies pending FDA approvals from Biogen, Eisai, and Denali Therapeutics, 2022 has put neurodegenerative drug development back on the map. Building on the field's momentum, we are delighted to bring back the 11th Alzheimer's and Parkinson's Drug Development Summit, dedicated to overcoming the translational challenges of targeting neurodegenerative mechanisms. This summit will unite neurodegenerative biopharma experts from discovery, preclinical, translational, and clinical backgrounds to showcase the latest breakthroughs in Alzheimer's, Parkinson's, and related neurological disorders in 2022 and 2023. URLs:Tickets: https://go.evvnt.com/1401329-1?pid=5569 Brochure: https://go.evvnt.com/1401329-3?pid=5569 Date and Time: On Tue, Feb 21, 2023 ( 9:00 AM) - Thu, Feb 23, 2023 ( 5:30 PM) Venue details: Hyatt Centric Fisherman's Wharf San Francisco, 555 North Point Street, San Francisco, California, 94133, United States Prices:Conference + Pre-Conference Workshop Day - Drug Developer: USD 4946.00,Conference + Novel CNS Biomarker Day - Drug Developer: USD 4946.00,Conference Only - Drug Developer: USD 2999.00,Conference + Pre-Conference Workshop Day - Service Provider Pricing: USD 5846.00,Conference + Novel CNS Biomarker Day - Service Provider Pricing: USD 5846.00,Conference Only - Service Provider Pricing: USD 3599.00 Speakers: Rachel Angers Associate Director, Neurodegeneration UCB, Sandra Banack Senior Scientist Brain Chemistry Labs, Habib Baghirov Scientific Lead Roche, Jay Barth Executive Vice President and Chief, Medical Officer Lexeo Therapeutics, Karen He Scientist, Disease Genetics Janssen, Tien Dam Executive Medical Director - Neurodegeneration Development Unit, Head of Movement Disorders Biogen, Cheng Fang Senior Vice President, Research and Development Annovis Bio, Sarah Huntwork-Rodriguez Associate Director, Biomarkers Denali Therapeutics Inc., Dimitrios Kapogiannis Senior Investigator, Chief of Human Neuroscience Section NINDS/NIH, Henri Huttunen Chief Scientific Officer Herantis Pharma Plc, Judith Kelleher-Andersson Chief Executive Officer and President Neuronascent, Sam Jackson Chief Medical Officer Neuron23, Viktoria Kheifets Senior Vice President Alkahest, Jeffrey Kordower Professor and Founding Director, ASU-Banner Neurodegenerative Disease Research Center Rush University Medical Center, Justine Manos Principal Research Scientist II Abbvie Inc., Rouba Kozak Global Biomarker Diagnostic and Neuroscience Lead Novartis AG, Meriel Owen Associate Director, Search and Evaluation Alzheimer's Drug Discovery, Jacob Marcus Director Merck and Co, Luis Miguel Oliveira Senior Associate Director - Research Programs The Michael J. Fox Foundation for Parkinson's Research, Bruce Morimoto Vice President, Drug Development Alto Neuroscience, Ryan Schubert Senior Vice President Translational Medicine and Clinical Strategy ASCENEURON, Andrea Small-Howard President and Chief Science Officer GrowBlox Sciences OTCQB, Ana Cristina Puhl Associate Director Collaborations Pharmaceuticals Inc., Anindya Sen Executive Director Prevail Therapeutics, Milton Werner President and Chief Scientific Officer Inhibikase Therapeutics, Steve Stice Co-Founder and Chief Scientific Officer ArunA Bio, Gregory Stewart Consultant Alcyone Life Sciences, Diane Stephenson Executive Director, Critical Path for Parkinson's Critical Path Institute, Gayle Wittenberg Vice President - Neuroscience Data Science and Digital Health Johnson and Johnson Services, Inc, Jian Yang Associate Vice President, Digital Health Research and Development Eli Lilly and Co., Hiu Zhang Senior Director Eli Lilly and Co.